These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

75 related articles for article (PubMed ID: 27488866)

  • 21. Cellular immune responses in asymptomatic human immunodeficiency virus type 1 (HIV-1) infection and effects of vaccination with recombinant envelope glycoprotein of HIV-1.
    Gorse GJ; Simionescu RE; Patel GB
    Clin Vaccine Immunol; 2006 Jan; 13(1):26-32. PubMed ID: 16425996
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Increased Levels of Macrophage Inflammatory Proteins Result in Resistance to R5-Tropic HIV-1 in a Subset of Elite Controllers.
    Walker WE; Kurscheid S; Joshi S; Lopez CA; Goh G; Choi M; Barakat L; Francis J; Fisher A; Kozal M; Zapata H; Shaw A; Lifton R; Sutton RE; Fikrig E
    J Virol; 2015 May; 89(10):5502-14. PubMed ID: 25740989
    [TBL] [Abstract][Full Text] [Related]  

  • 23. HIV-1 infection dynamics and optimal control with Crowley-Martin function response.
    Naeem Jan M; Ali N; Zaman G; Ahmad I; Shah Z; Kumam P
    Comput Methods Programs Biomed; 2020 Sep; 193():105503. PubMed ID: 32387782
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Predicting the potential impact of a cytotoxic T-lymphocyte HIV vaccine: how often should you vaccinate and how strong should the vaccine be?
    Smith RJ; Schwartz EJ
    Math Biosci; 2008 Apr; 212(2):180-7. PubMed ID: 18359048
    [TBL] [Abstract][Full Text] [Related]  

  • 25. HIV immunotherapy comes of age: implications for prevention, treatment and cure.
    Routy JP; Mehraj V; Cao W
    Expert Rev Clin Immunol; 2016; 12(2):91-4. PubMed ID: 26629806
    [TBL] [Abstract][Full Text] [Related]  

  • 26. A dendritic cell-based vaccine for treating HIV infection: background and preliminary results.
    Andrieu JM; Lu W
    J Intern Med; 2007 Feb; 261(2):123-31. PubMed ID: 17241177
    [TBL] [Abstract][Full Text] [Related]  

  • 27. A mathematical model of HIV infection: Simulating T4, T8, macrophages, antibody, and virus via specific anti-HIV response in the presence of adaptation and tropism.
    Wasserstein-Robbins F
    Bull Math Biol; 2010 Jul; 72(5):1208-53. PubMed ID: 20151219
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Rates of HIV immune escape and reversion: implications for vaccination.
    Davenport MP; Loh L; Petravic J; Kent SJ
    Trends Microbiol; 2008 Dec; 16(12):561-6. PubMed ID: 18964018
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Safety and immunogenicity of an adjuvanted protein therapeutic HIV-1 vaccine in subjects with HIV-1 infection: a randomised placebo-controlled study.
    Harrer T; Plettenberg A; Arastéh K; Van Lunzen J; Fätkenheuer G; Jaeger H; Janssens M; Burny W; Collard A; Roman F; Loeliger A; Koutsoukos M; Bourguignon P; Lavreys L; Voss G
    Vaccine; 2014 May; 32(22):2657-65. PubMed ID: 24144472
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Optimal Control Strategies and Sensitivity Analysis of an HIV/AIDS-Resistant Model with Behavior Change.
    Rabiu M; Willie R; Parumasur N
    Acta Biotheor; 2021 Dec; 69(4):543-589. PubMed ID: 34331152
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The Effects of Time Lag and Cure Rate on the Global Dynamics of HIV-1 Model.
    Ali N; Zaman G; Abdullah ; Alqahtani AM; Alshomrani AS
    Biomed Res Int; 2017; 2017():8094947. PubMed ID: 28691034
    [TBL] [Abstract][Full Text] [Related]  

  • 32. A randomized controlled trial of HIV therapeutic vaccination using ALVAC with or without Remune.
    Angel JB; Routy JP; Tremblay C; Ayers D; Woods R; Singer J; Bernard N; Kovacs C; Smaill F; Gurunathan S; Sekaly RP
    AIDS; 2011 Mar; 25(6):731-9. PubMed ID: 21330911
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Two types of cytotoxic lymphocyte regulation explain kinetics of immune response to human immunodeficiency virus.
    Rouzine IM; Sergeev RA; Glushtsov AI
    Proc Natl Acad Sci U S A; 2006 Jan; 103(3):666-71. PubMed ID: 16407101
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Relationship between CD38 expression on peripheral blood T-cells and monocytes, and response to antiretroviral therapy: a one-year longitudinal study of a cohort of chronically infected ART-naive HIV-1+ patients.
    Almeida M; Cordero M; Almeida J; Orfao A
    Cytometry B Clin Cytom; 2007 Jan; 72(1):22-33. PubMed ID: 17051525
    [TBL] [Abstract][Full Text] [Related]  

  • 35. A phase I evaluation of the safety and immunogenicity of vaccination with recombinant gp160 in patients with early human immunodeficiency virus infection. Military Medical Consortium for Applied Retroviral Research.
    Redfield RR; Birx DL; Ketter N; Tramont E; Polonis V; Davis C; Brundage JF; Smith G; Johnson S; Fowler A
    N Engl J Med; 1991 Jun; 324(24):1677-84. PubMed ID: 1674589
    [TBL] [Abstract][Full Text] [Related]  

  • 36. T-cell vaccination against anti-CD4 autoimmunity in HIV-1 infected patients.
    Abulafia-Lapid R; Bentwich Z; Keren-Zur Y; Cohen IR; Atlan H
    J Clin Virol; 2004 Dec; 31 Suppl 1():S48-54. PubMed ID: 15567094
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Safety and immunogenicity of the HPV-16/18 AS04-adjuvanted vaccine in HIV-positive women in South Africa: a partially-blind randomised placebo-controlled study.
    Denny L; Hendricks B; Gordon C; Thomas F; Hezareh M; Dobbelaere K; Durand C; Hervé C; Descamps D
    Vaccine; 2013 Nov; 31(48):5745-53. PubMed ID: 24091311
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Development and preclinical safety evaluation of a new therapeutic HIV-1 vaccine based on 18 T-cell minimal epitope peptides applying a novel cationic adjuvant CAF01.
    Fomsgaard A; Karlsson I; Gram G; Schou C; Tang S; Bang P; Kromann I; Andersen P; Andreasen LV
    Vaccine; 2011 Sep; 29(40):7067-74. PubMed ID: 21767590
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Mathematical model of the effect of affinity hemodialysis on the T-cell depletion leading to AIDS.
    Tullis RH
    Blood Purif; 2004; 22(1):84-91. PubMed ID: 14732816
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Effect of therapeutic immunization with HIV type 1 recombinant glycoprotein 160 ImmunoAG vaccine in HIV-infected individuals with CD4+ T cell counts of >or=500 and 200-400/mm3 (AIDS Clinical Trials Group Study 246/946).
    Kundu-Raychaudhuri S; Sevin A; Kilgo P; Nokta M; Pollard RB; Merigan TC
    AIDS Res Hum Retroviruses; 2001 Oct; 17(15):1371-8. PubMed ID: 11679149
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 4.